SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Identificadores![](/xmlui/themes/Mirage2//images/despl_identif.png)
Identificadores
Visualización o descarga de ficheros![](/xmlui/themes/Mirage2//images/despl_contenidos.png)
Visualización o descarga de ficheros
Fecha de publicación
2019Título de revista
Clinical & Translational Oncology
Tipo de contenido
Artigo
DeCS
carcinoma | pronóstico | tratamiento combinado | inmunoterapia | ensayos clínicos como asunto | radioterapia | humanos | guías de práctica clínica como asunto | neoplasias pulmonaresMeSH
Immunotherapy | Clinical Trials as Topic | Lung Neoplasms | Carcinoma | Radiotherapy | Humans | Combined Modality Therapy | Practice Guidelines as Topic | PrognosisResumen
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment attains greater value.
![](/xmlui/themes/Mirage2//images/final_lines.png)